Physostigmine in Alzheimer's disease: effects on cognitive functioning, cerebral glucose metabolism analyzed by positron emission tomography and cerebral blood flow analyzed by single photon emission tomography
Citations Over TimeTop 23% of 1991 papers
Abstract
The effect of acute, intravenous administration of physostigmine on measures of brain activity and cognitive functioning were investigated in 14 patients with Alzheimer's disease. Regional cerebral glucose metabolism was assessed using (18F)-fluoro-2-deoxy-D-glucose and positron emission tomography, and cerebral blood flow was assessed using 123I-iodoamphetamine single photon emission tomography. Although physostigmine enhanced cerebral blood flow in most patients, only one patient showed significant clinical improvement. This patient, however, also showed a very pronounced improvement in cerebral glucose metabolism. It is concluded that these preliminary findings hold considerable promise for our appreciation of the pathophysiology of dementing illness as well as our understanding of centrally acting compounds of interest in Alzheimer's disease.
Related Papers
- → Serial single photon emission computed tomography imaging in patients with cerebral lupus during acute exacerbation and after treatment(1997)16 cited
- → Left hemispheric reductions of regional cerebral blood flow (rCBF) correlate with measures of dementia severity in patients with Alzheimer's disease: a SPECT study(1996)4 cited
- Evaluation of a 99Tcm bound brain scanning agent for single photon emission computed tomography.(1986)
- → An overview of the contribution of regional cerebral blood flow studies in cerebrovascular disease: Is there a role for single photon emission computed tomography?(1990)29 cited
- The use of 123I-iodoamphetamine and single-photon emission computed tomography to assess local cerebral blood flow.(1983)